Monotherapy in patients inadequately controlled by diet & exercise alone & for whom metformin is inappropriate due to contraindications or intolerance. Dual oral therapy in combination w/ metformin when diet & exercise + metformin alone do not provide adequate glycaemic control; in combination w/ a PPARγ agonist (eg, thiazolidinedione) when use of a PPARγ agonist is appropriate & when diet & exercise + PPARγ agonist alone do not provide adequate glycaemic control. Triple oral therapy in combination w/ sulphonylurea & metformin when diet & exercise + dual therapy do not provide adequate glycaemic control; in combination w/ a PPARγ agonist & metformin when use of a PPARγ agonist is appropriate & when diet & exercise + dual therapy w/ these products do not provide adequate glycaemic control. Add-on to insulin (w/ or w/o metformin) when diet & exercise + stable dose of insulin do not provide adequate glycaemic control.